MicroRNAs (miRNAs) belong to the heterogeneous class of non-coding RNAs (ncRNAs), which are by definition RNA molecules that do not encode for proteins, but have instead important structural, catalytic or regulatory functions. In this review we first provide an overview of the different ncRNA families, focusing in particular on miRNAs and their relevance in tumour development and progression. Second we shortly describe the available ncRNA expression profiling methods, which comprise microarray, bead-based hybridization methods, in situ hybridization, quantitative real-time polymerase chain reaction, cloning and deep sequencing methods. Finally, we used the PubMed database to perform an extensive literature search for miRNA expression profiling research articles in cancer and identified 58 studies that were published between 2004 and 2009; we identified 70 miRNAs that were reported in at least five studies as being either up-or downregulated, depending on the type of cancer, and 192 miRNAs that were reported to be up-or downregulated in at least two reports. MiRNA expression profiling of human tumours has identified signatures associated with diagnosis, staging, progression, prognosis, and response to treatment.
Regulatory Non-Coding RNAs as Newly Discovered Members of the Genome Architecture
Non-coding RNAs (ncRNAs) are defined as RNAs that do not encode proteins (1, 2) . Until a decade ago, ncRNA genes were invisible even by complete genome sequencing. A central tenet of molecular biology is that RNA plays the role of intermediate messenger between the gene and the final protein encoded by this gene (1-3). Scientists discovered prevalent roles for ncRNA that were based on specific nucleic acid recognition without any catalytic function (as were identified for ribosomes) (1). NcRNA genes produce transcripts that function as structural, catalytic, or regulatory RNAs (1, 4, 5) . Some groups of ncRNAs have been known for a long time and have well-known functions in cell life. Some of them are involved in RNA translation mechanisms (ribosomal RNA [rRNA] and transfer RNA or in Technology in Cancer Research & Treatment, Volume 9, Number 2, splicing (small nuclear RNA [snRNA]), and some are known to have the ability to modify other groups of ncRNA, such as small nucleolar RNAs (snoRNA) that modify rRNA (2). Many ncRNAs have to be alternatively spliced or/and processed into smaller RNA molecules to become functional (2). RNA molecules, in general, have wide biological functions on all levels of gene regulation, mainly influencing transcription initiation, messenger RNA (mRNA) stability, RNA editing, splicing, and even control of chromosome dynamics (i.e., maintenance and segregation). RNA molecules might have influence on cell cycle regulation and were found to function in response to stress (hypoxia); furthermore, they contribute to cell death or apoptosis (2, (6) (7) (8) (9) . The regulatory function of ncRNA mainly relies on base-pairing with complementary sequences of RNA from other RNA classes or of DNA from promoter regions, so they can form RNA:RNA or RNA:DNA complexes. But otherwise base-pairing is not the only way how ncRNA can influence on their targets (2).
Recently, tiling array experiments (i.e., arrays with probes designed to cover the entire genome) suggested that the majority of the genomes of mammals and other complex organisms are actually transcribed into ncRNA and not into mRNAs. In last few years, the number of identified ncRNAs has increased very quickly and is still rising suggesting that our understanding of the genome structure and components of functional networks is far from complete (10); by now more than 900 unique ncRNA sequences have been identified based upon extensive literature research (2, 11) and recently showed there are way more than 1000 ncRNAs encoded in mammal genome (12, 13) .
The most thoroughly studied class of ncRNAs is by far the microRNA (miRNA) class (14) , and the variation of miRNA expression in cancer cells is the main topic of this review. Much longer non-coding transcripts, such as ultraconserved transcripts or ultraconserved genes (UCGs), were also cloned, but their functions in normal cells and abnormalities in cancer cells have not been fully explored (15) .
As ncRNAs represent a very heterogeneous group, they can be subgrouped in different classes based on their length and finally their function: (i) miRNAs; (ii) other small ncR-NAs (such as snoRNA, snRNA, and piwi-interacting RNA [piRNA]); and (iii) long ncRNAs.
After a brief description of ncRNA, we will describe miRNA profiling methods and finally we will summarize the major findings of miRNA profiling in cancer.
MiRNAs
MiRNAs represent most widely studied and very fast evolving group among ncRNA. Their size range from 18 nucleotides to approximately 25 nucleotides and according to many reports miRNAs control expression of at least one-third of human protein-coding genes (16, 17) . In the cell, miRNAs are processed from hairpin structures named precursor miRNAs (18). Posttranscriptional regulation due to miRNA can occur either by non-perfect pairing, which causes suppression of transcription, or by perfect-match pairing, which provokes degradation of target mRNAs (19) . MiRNA duplexes are recognized by the multi-protein infrastructure known as RNA-induced silencing complex, which is part of the posttranscriptional regulatory mechanism named RNA interference (2). Because of miRNA "power" in controlling gene expression, miRNAs are involved in a wide range of developmental processes, cell-cycle regulation, and supervision of cell fate (2). Studies of miRNA expression have revealed tissue-or cell-specific expression patterns, and differences between normal and cancer tissue of same cellular origin are ubiquitous (20) (21) (22) . Changes in miRNA expression profiles, in their specific sequences, and in "interactor" sites in mRNA targets have been identified in a variety of human genetic diseases, including cancer, heart disease, diabetes, and neural disorders (2, 10, 23-26, Figure 1 ). Most current research on miRNA in cancer is focusing on creating a diagnostic tool for cancer classification and a possible prognostic tool to define disease stage and progression (27) (28) (29) .
Description of other small RNAs like snoRNA, snRNA, and piRNA or also called non-miRNA small RNAs can be read in following references (2, 11, 30) .
Long ncRNAs
Initially, long ncRNAs were considered to be background noise associated with RNA polymerase activity (31, 32). Further detailed investigations, however, have proven long ncRNA involvement in fundamental cellular processes such as RNA processing, gene regulation, chromatin modification, gene transcription (controlling the RNA polymerase II activity taking part as cofactors in RNA-protein complexes), posttranscriptional gene regulation (splicing, editing, transport, translation, and degradation) based on RNA sequence complementarity interactions, and other functions yet to be discovered (32) (33) (34) (35) (36) (37) . This long ncRNAs also include a recently identified group of ncRNAs named ultraconserved genes (UCGs) that are transcribed from ultraconserved genomic regions (UCRs) (15), and that have a tissue specific expression pattern (7, 15) . Researchers became aware of UCRs when alignment of human, rat, and mouse genomes showed that, despite 300 million years of negative selection, there were genomic regions that remained highly conserved (100% identity) (32, 33) . In fact, UCRs are even more conserved than coding genes and are now believed to have fundamental functions in vertebrate evolution, including that of mammals (33, (38) (39) (40) . UCRs are frequently observed in fragile genomic regions that are usually associated with cancers, and the expression of UCGs in several human carcinomas and leukemias is aberrant with respect to the normal tissue counterpart (15). Signatures of deregulated UCGs are cancer-specific and have prognostic implications. Similar to miRNAs, UCGs can act as oncogenes or tumour-suppressor genes, and UCG expression is controlled by miRNAs (15).
MiRNA Expression Profiling Methods
Profiling of miRNA is used to document miRNA expression variability, and it was found to be more accurate for cancer classification than using whole sets of known protein-coding genes (20) . Besides disease prognosis, profiling of miRNA may be used for defining disease markers and, in some cases, even to predict cancer therapy outcome (41, 42) . Several techniques are currently available for gaining information about miRNA signatures; the most frequently used techniques are presented in Table I and Figure 2 . Northern blot analysis was considered the gold standard for gene expression detection and quantification before the development of microarray analysis. The first high-throughput technology was miRNA microarray analysis, which was initially developed in Carlo Croce's laboratory (43). Other than microarray, frequently used strategies for miRNA profiling are quantitative real-time polymerase chain reaction (qRT-PCR), bead-based hybridization, cloning, and deep sequencing (40, 52) . Each technique is based on different principles, and all have some advantages and disadvantages (Table I) . Evolution of miRNA high-throughput analysis happened fast. Methods for analyzing miRNA can be classified into two general categories, which distinguish methods according to the possibility of discovering new miRNA ( Figure 2 ). Most methods are based on hybridization (microarray, bead-based flow cytometry, and in situ hybridization [ISH]); some are based on amplification (qRT-PCR and sequencing), and the best combine both principles (cloning) (43, 52, 53) . 
Profiling of Known MiRNAs

MiRNA Microarrays
This first microarray method for complementary DNA (cDNA) hybridization was described in 1995 by Schena et al., (54) . The major advantage of this method was the ability to simultaneously test multiple genes in numerous samples, which provided a large amount of information and saved time. It is now recognized that the miRNA microarray method should be used only as a starting investigation in miRNA expression screening/profiling and should be followed by other profiling techniques for validation purposes, such as qRT-PCR (43). Multiple types of microarray are available, based on distinct principles and technologies, varying in their. Microarrays can differ in the way in which and the surface on which probes are spotted (i.e., by hand or machine, on glass or quartz), in the way probes are designed (this represents a difficult task because of miRNAs small size), synthesized (possibly directly on the surface), and modified as well as in the amount of probe or sample needed. The main disadvantage of using handspotted probes in microarrays is the amount of RNA sample needed for analysis (to 30 µg); current use of precisely automated machines has solved this issue reducing considerably the amount of RNA needed (43, 52, 55) . Automation also offers the advantage to spot a higher number of probes on the same slide, and therefore to test a higher number of miRNAs at the same time, even when probes recognizing both mature and premature miRNAs are included (52). Furthermore, according to the aim of the experiment (sample comparison or expression testing of a single sample) the type of array used can be different (43, 55, 56) . Finally, sample preparation and labelling also varies depending on the array used and on the need to recognize different forms of miRNA (i.e., mature and precursor), and can require or not amplification, retrotranscription and enrichment for small RNAs (43).
Bead-Based Hybridization
Advantages of the bead-based hybridization for miRNA profiling are its high specificity, sensitivity, and efficiency (44). The protocol starts by ligating an adaptor molecule to a small RNA, followed by adaptor-specific reverse transcription (i.e., primers aligning to the adaptor), and then PCR amplification with primers antisense to the adaptor sequence is being subsequent (one of which is labeled with biotin). The biotinlyated PCR product is then hybridized with miRNA-specific probes bound to fluorescent beads. Known miRNA-specific signals that are produced together with the beads and marked PCR products are measured and read with a flowcytometer. For each miRNA that is known, a complementary probe and mixture of fluorescent dyes have been made to distinguish and decipher the miRNA when its signal is detected (44, 52). The bead-based hybridization technique is overall time consuming and strenuous. As for miRNA microarrays, this method is limited in that only known miRNAs can be detected, but still has the advantage that known miRNAs can all be assayed in a single run (52). Another main advantage is that the RNA input required can be as low as 100 ng. This technique is relatively new and not as commonly used as other miRNA profiling techniques, nevertheless its accuracy and reliability has been provided by the evidence that miRNA expression profiles generated by bead-based hybridization are highly comparable to profiles gained with qRT-PCR or direct sequencing (44).
MiRNA In Situ Hybridization (ISH) with Locked Nucleic Acid Probes
MiRNA ISH is the only method that renders the location of RNA visible on a histology section. Briefly, the ISH method detects miRNA by creating a reaction between the miRNA and the labelled miRNA-specific locked nucleic acid (LNA) probes. Benefits of LNA probes are their thermal stability and mismatch discrimination in hybridization; for this reason LNA probes are also used in other expression profiling platforms, for single nucleotide polymorphism (SNP) genotyping and for antisense-based gene silencing assays (57, 58) . MiRNA ISH greatest strengths are its ability to preserve RNA integrity (no cell lysis is performed) and identify the actual locations of miRNA inside tissues or cell compartments (45, 57) . The efficiency of ISH depends on the miRNA copy number (the higher the better), probe length and concentration, and hybridization set-up conditions (stringency) (45, 57) . The several published protocols differ mainly in regard to the presence or not of a of protease prehybridization step, the molecule used for labelling the probes (either fluorescein isothiocyanate or digoxigenin), the probe concentration, the hybridization temperature and duration, and whether or not signal amplification is required (45) . Common problems in LNA-based ISH are strong background signal and feeble miRNA signal especially in samples with low miRNA copy number, both of which can be solved by simply increasing the probe concentration (45) . Although this is a low throughput approach (one probe for one miRNA), this is the only techniques for miRNA profiling that can evaluate miRNA expression in a single cell and can be used to screen for single miRNA molecules in human cancer tissue sections and animal embryos (57, 59).
MiRNA qRT-PCR detection
PCR-based profiling was the ideal solution for some of the problems encountered with microarray profiling, such as the need for large amount of RNA. In fact, the PCRbased miRNA profiling method has the capacity to detect miRNAs with very low copy number (46), which is important because large amounts of RNA from clinical samples can be difficult to obtain. Advantages of qRT-PCR-based techniques are a high level of sensitivity, specificity, and affordability (60). qRT-PCR offers the possibility of early cancer diagnosis, detection of disease progression, cancer classification (when histopathological findings are indeterminate), screening for RNA genes responsible for diseases, and a new approach in monitoring treatment efficacy (Table II) (29, 60) . MiRNA expression analysis by qRT-PCR technique is also widely used to confirm the most significant results obtained from miRNA microarray genome-wide profiling (60). However, qRT-PCR also has some technical limitations.
Because miRNAs are short and intronless, for miRNA expression analysis to be reliable, it is necessary to remove genomic DNA from cDNA by deoxyribonuclease treatment (46). The RNA samples have to have the poly[A] tail to give the reverse transcriptase (RT) the necessary template to start reverse transcription; since mature miRNAs have lost their poly[A] tail after the processing steps, appropriate primers (miRNA specific or random hexamers) are used (46). miRNA specific stem-looped primers in the RT reaction can also be used, and these avoid the need to remove genomic DNA from the sample, since stem-looped primers cannot anneal to RNA molecules (such as precursor miRNA) or DNA fragments that don't have the exact sequence and length of the target miRNA. Once the cDNA is ready, the next step is amplification of the target gene by the qRT-PCR. The qRT-PCR method is very specific; thus, technical limitations are usually the consequence of experiment design, including poor sample selection, poor RNA isolation and handling, improper normalization of gene expression, and absence of adequate controls (such as reverse transcription without enzyme and contamination controls (46, 47) .
Profiling of Known and Newly Identified MiRNAs
Cloning Cloning is used for concomitant discovery of novel miRNA in samples. In fact, most miRNAs were discovered by the cloning profiling method (61). However, the cloning method has several weaknesses, including its ability to quantify the amount of miRNA in a sample; with this method, it is hard to detect and isolate miRNAs that have low expression or are unstable or tissue specific (43). Cloning will fail if the investigation does not choose the right genomic region to analyze and the procedure is technically challenging (62). Many times cloning is used as a first step in miRNA analysis (48).
Deep Sequencing
Deep sequencing methods (also known as next-generation sequencing, de novo sequencing, or second generation sequencing) have been applied for miRNAs profiling; they display a high sensitivity and the potential to discover novel ncRNA. Deep sequencing also allows the simultaneous sequencing of several different RNA molecules, including small RNAs (53). The Sanger method, introduced in the late 1970s, was the first sequencing method developed and was presented as a capillary-based approach (63). In the past few years, the meaning of "sequencing" has evolved and the new approaches to sequencing are considered "second generation" sequencing techniques (50). De novo sequencing methods generally differ from Sanger's for reagents, equipment, bioinformatic software for data analysis, but most importantly for their higher detection capability and versatility (from detection of polymorphism, mutation, methylation, or structural variation all the way to gene expression and miRNA profile) (50, 51, 64). The existing deep sequencing platforms differ for chemistry principles used, amplification approach, efficiency, duration, expense, accuracy, error distribution, and tolerance of minimum sequence length (from 13 to 250 bp) (50, 51, 65).
Compared with other high-throughput assays, such as microarray (the current standard method for profiling), deep sequencing technologies are not subject to the problems of background noise and cross hybridization (66). Information gained via deep sequencing reflects actual picture of the miRNA profile; also, de novo sequencing allows the discovery of novel miRNAs or ncRNAs that have not been previously identified via cloning or sequencing (53). Unlike microarray analysis, deep sequencing methods are expensive for routine laboratory work, so deep sequencing is not commonly used in the research laboratory; however, it will be used more as it becomes affordable for researchers (50, 53) . Another disadvantage of the deep sequencing method is the amount of RNA used (10 µg) and the fact that the purification of RNA required for this method causes some of the RNA to be lost (53).
With the fast evolution of technology, the "third generation" of sequencing will be available to researchers in the near future. This technique is based on nano-pore technology and is able to read the diploid mammalian genome in approximately 24 hours at much lower costs than second generation sequencing, which require even more time (4-5 days) (51, 67, 68). 
MiRNA Profiling of Cancer
MiRNAs have been proven to be involved in cancer development and progression (20, 69) . A plethora of studies published in the last 5 years have reported differences in miRNA profiles of cancer cells. For this review, we conducted a wide literature search of studies on miRNA genome-wide profiling in cancer tissue or cell lines published between August 2004, when the first genome-wide profiling study in cancer was published (70), and October 2009 using the PubMed database as the sole resource. We used the following search terms: microRNA, expression, profile, cancer, and expression profiles. We found 58 studies and from these studies we collected data on miRNAs that were reported to be up-or downregulated in different types of cancer tissue or cells. Table II shows the 70 miRNAs reported to be differentially expressed between normal and cancer tissues or cells in at least five of the independent studies, while Supplementary  Table SI includes all 192 miRNAs identified as being abnormally expressed in cancer cells in at least two reports (27, 28, 42, . All the studies used for review are listed in Supplementary types of cancer. Two groups of researchers (one in China and the other in the United States) together conducted wide cohort studies to monitor patients with colon adenocarcinoma; the groups tried to identify associations between miRNA expression profiles and cancer prognosis and therapeutic outcome according to patient survival (42). They distinguished expression profiles of miRNAs in colon adenocarcinoma and found that overexpression of miR-21 was associated with poor survival and poor response to adjuvant chemotherapy. In patients receiving chemotherapy, high miR-21 expression in tumours predicted a shorter overall survival, which gives preliminary support to the hypothesis that high miR-21 expression is associated with poor therapeutic outcome (42).
Conclusion
In conclusion, miRNAs are involved in the regulation of pathways active in tumour development and progression. The question of whether miRNAs represent the "dark side" of cancer predisposition will soon be answered by large-scale studies of patients with hereditary cancers the use of miRNAs as colorectal carcinoma biomarkers is a nascent field, and the potential exploitation of miRNAs represents a future therapeutic option for medical oncologists.
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Authors state that there are no conflicts of interest. methods of miRNA expression profiling and confirmation of expression. The most common method used for expression profiling was microarray, but other approaches, such as the bead-based method, were also used. After high-throughput procedures and data analyses, some miRNAs were confirmed by qRT-PCR, Northern blot, ISH, or other methods. Here, we will focus on a few significant examples of miRNA profiles that can be very useful in tumour classification, prognosis, and prediction of the therapeutic outcome.
MiRNA Profiling as a Diagnostic Tool Lu et al., (27) discovered that miRNA profiles contain much information that could be used to explain the developmental processes and differentiation state of tumours. They observed a general downregulation of miRNAs in tumour samples compared to normal samples by using bead-based expression profiling (27). Also, researchers were able to use profile data to classify human cancers even if they were poorly differentiated from one another (27). Volinia et al., (75) also tried to define the miRNA signature for human solid tumours by using microarray expression profiling. While their results did not confirm the general downregulation of miRNAs in tumour samples, they did define miRNAs that can be used to classify tumours (breast, colon, lung, pancreas, prostate, and stomach); three of the defined miRNAs (has-miR-21, -191, and -17-5p) were overexpressed in all six solid cancers (75).
MiRNA Profiling as a Prognostic Tool
Several studies of miRNA in cancers have demonstrated that aberrant miRNA expression signatures can reveal distinct subgroups of each cancer type. Calin et al., (28) reported that a specific miRNA expression signature consisting of 13 miR-NAs in human chronic lymphocytic leukemia is linked to disease progression from the time of diagnosis to the time patient begins therapy. To identify miRNA expression patterns associated with colon adenocarcinoma prognosis and therapeutic outcome, Schetter et al., (42) , using cancer-specific death as their end point, reported that miRNAs were differentially expressed in colon adenomas and carcinomas and that miRNA expression patterns were associated with survival. They concluded that expression patterns of miRNAs are systematically altered compared to normal colon mucosa as colon adenomas progress to adenocarcinomas (42). Other studies have found that specific miRNA profiles are associated with poor prognosis in ovarian cancer and tumour progression in breast cancer (87, 93) and have identified let-7b, miR-18a, miR-93, miR-141, miR-199a, miR-200, and miR-429 as prognosis predictors (93) .
MiRNA Profiles as Predictors of Response to Therapy
High expression of miR-21 in particular has been associated with poor survival and poor therapeutic outcome in many
